Clinical Trials in North Canton, Ohio
24 recruiting
Showing 1–20 of 24 trials
Recruiting
Phase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Major Depressive Disorder (MDD)Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.153 enrolled16 locationsNCT07284667
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Treatment Resistant Depression
atai Therapeutics, Inc.142 enrolled48 locationsNCT06524830
Recruiting
Phase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Early Alzheimer's Disease
Merck Sharp & Dohme LLC340 enrolled75 locationsNCT07033494
Recruiting
Phase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Schizophrenia
LB Pharmaceuticals Inc.456 enrolled13 locationsNCT07363577
Recruiting
Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pediatric Migraine
Pfizer2,100 enrolled109 locationsNCT04649242
Recruiting
Phase 3
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Major Depressive Disorder
Cybin IRL Limited220 enrolled46 locationsNCT06564818
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled74 locationsNCT06951711
Recruiting
Phase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bipolar Disorder Type I With Mania
Bristol-Myers Squibb450 enrolled170 locationsNCT06929273
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Memory DisordersMild Cognitive ImpairmentMemory Impairment+3 more
GAP Innovations, PBC1,200 enrolled26 locationsNCT06584357
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bipolar-I Disorder With Mania or Mania With Mixed Features
Bristol-Myers Squibb274 enrolled63 locationsNCT06951698
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled11 locationsNCT07105098
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 1
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Sickle Cell Disease
Fulcrum Therapeutics24 enrolled6 locationsNCT07431398
Recruiting
Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Sickle Cell DiseaseThalassemia
Novo Nordisk A/S480 enrolled103 locationsNCT06609226
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious Distress
Seaport Therapeutics360 enrolled45 locationsNCT07065240
Recruiting
Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Generalized Anxiety Disorder
Definium Therapeutics US, Inc.250 enrolled38 locationsNCT06809595
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled74 locationsNCT06058013
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.705 enrolled69 locationsNCT06480383